Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.
暂无分享,去创建一个
[1] S. Rajkumar,et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. , 2003, Journal of the American Academy of Dermatology.
[2] S. Gillessen,et al. Thalidomide: from tragedy to promise. , 2003, Swiss medical weekly.
[3] P. Bouche,et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. , 2002, The Journal of investigative dermatology.
[4] F. Kontopidou,et al. Thalidomide in the treatment of myelodysplastic syndrome with fibrosis. , 2002, Leukemia research.
[5] M. Baccarani,et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. , 2002, Blood.
[6] B. Barlogie,et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. , 2002, Blood.
[7] I. Yakoub-Agha,et al. Efficacy of a low dose of thalidomide in advanced multiple myeloma. , 2002, Blood.
[8] J. English,et al. Diffuse cutaneous mucinoses. , 2002, Dermatologic clinics.
[9] Hannes Kaufmann,et al. Thromboembolic events during treatment with thalidomide. , 2002, Blood.
[10] S. Rajkumar,et al. Deep venous thrombosis and thalidomide therapy for multiple myeloma. , 2001, The New England journal of medicine.
[11] A. Rebora,et al. Cutaneous Mucinoses: Microscopic Criteria for Diagnosis , 2001, The American Journal of dermatopathology.
[12] A. Rebora,et al. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. , 2001, Journal of the American Academy of Dermatology.
[13] I. Forgacs,et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). , 2000, Journal of the American Academy of Dermatology.
[14] E. Bisaccia,et al. Scleromyxedema with dermato-neuro syndrome. , 2000, Journal of the American Academy of Dermatology.
[15] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[16] A. Pandya,et al. Fatal scleromyxedema: report of a case and review of the literature. , 1998, Journal of the American Academy of Dermatology.
[17] C M Lockwood,et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures , 1995, Clinical and experimental immunology.
[18] E. Atra,et al. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. , 1993, Clinical and experimental rheumatology.
[19] P. Richardson,et al. Thalidomide: emerging role in cancer medicine. , 2002, Annual review of medicine.
[20] Black Mm,et al. The dermal mucinoses. , 1993 .